Advertisement

References

• Centers for Disease Control and Prevention (CDC). Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2012. HIV Surveillance Supplemental Report 2014;19(No. 3). http://www.cdc.gov/hiv/library/reports/surveillance/. Published November 2014. Accessed July 6, 2015.
• Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. Published November 2013. Accessed July 6, 2015.
• Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia—Los Angeles. Morbidity and Mortality Weekly Report (MMWR) 1981;30:1–3. http://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm. Accessed December 18, 2015.
• Gelezuinas R, Greene W. Molecular Insights into HIV-1 infection and pathogenesis. In: Sande MA, Volberding PA. The Medical Management of AIDS. 6th ed. Philadelphia, PA: Saunders; 1999:23–39.
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946–954.
• Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332:201–208.
• Centers for Disease Control and Prevention (CDC). HIV transmission risk. http://www.cdc.gov/hiv/policies/law/risk.html. Updated November 16, 2015. Accessed July 6, 2015.
• Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621–1629.
• Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33–39.
• Ridzon R, Gallagher K, Ciesielski C, et al. Simultaneous transmission of human immunodeficiency virus and hepatitis C virus from a needle-stick injury. N Engl J Med. 1997; 336:919–922.
• Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008; 3:10–15.
• U.S. Department of Health and Human Services (USDHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Considerations for antiretroviral use in special patient populations. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/20/acute-and-recent--early--hiv-infection. Published January 28, 2016. Accessed February 17, 2016.
• National Institutes of Health (NIH). Benefits of early antiretroviral therapy in HIV infection. http://www.nih.gov/news-events/nih-research-matters/benefits-early-antiretroviral-therapy-hiv-infection. Published August 10, 2015. Accessed February 17, 2016.
• Centers for Disease Control and Prevention (CDC). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report (MMWR) Recommendations and Reports 1992; 41:RR-17. http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed December 18, 2015.
• U.S. Department of Health and Human Services (USDHHS). Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Mucocutaneous candidiasis. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/331/candida. Published December 8, 2015. Accessed February 17, 2016.
• U.S. Preventive Services Task Force. Final recommendation statement: human immunodeficiency virus (HIV) infection: screening, April 2013. http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/human-immunodeficiency-virus-hiv-infection-screening. Accessed July 7, 2015.
• Moyer VA; U.S. Preventive Services Task Force. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159:51–60.
• Centers for Disease Control and Prevention (CDC). State HIV Testing Laws: Consent and Counseling Requirements. http://www.cdc.gov/hiv/policies/law/states/testing.html. Published March 18, 2015. Accessed February 17, 2016.
• Centers for Disease Control and Prevention (CDC) and Association of Public Health Laboratories. Laboratory testing for the diagnosis of HIV infection: updated recommendations. http://stacks.cdc.gov/view/cdc/23447. Published June 27, 2014. Accessed July 7, 2015.
• U.S. Department of Health and Human Services (USDHHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/guidelines. Updated January 28, 2016. Accessed February 24, 2016.
• Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, Infectious Disease Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis 2014; 58:e1–34.
• Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Updated June 17, 2013. Accessed July 7, 2015.
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21–30.
• U.S. Department of Health and Human Services (USDHHS). Side effects of anti-HIV medications: health information for patients. https://aidsinfo.nih.gov/contentfiles/sideeffectanithivmeds_cbrochure_en.pdf. Published October 2005. Accessed July 9, 2015.
• Deeks S, Lewin S, Havlir D. The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382:1525–1533.
• Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
• Centers for Disease Control and Prevention (CDC). U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014: A clinical practice guideline. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Published 2014. Accessed July 8, 2015.

Disclosures: Julianne Griswold, DO; nothing to disclose. Marisa Tungsiripat, MD; nothing to disclose.

< Summary